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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 86, Revision 2 
(FGE.86Rev2): Consideration of aliphatic and arylalkyl amines and amides 
evaluated by JECFA (65th meeting)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of 30 aliphatic and arylalkyl amines and amides evaluated by JECFA at the 65th meeting in 2005. This 
revision is required owing to additional available toxicity data on piperine [FL-no: 14.003] and deca-(2E,4E)-
dienoic acid isobutyl-amide [FL-no: 16.091]. The substances were evaluated through a stepwise approach that 
integrates information on structure-activity relationships, intake from current uses, toxicological thresholds of 
concern and available data on metabolism and toxicity. The Panel agrees with JECFA’s conclusion “No safety 
concern at estimated levels of intake as flavouring substances” based on the Maximised Survey-derived Daily 
Intake (MSDI) approach for all substances considered in this FGE. Besides the safety assessment of these 
flavouring substances, the specifications for the materials of commerce have also been considered and for all 30 
substances, the information is adequate. 
© European Food Safety Authority, 2015 
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SUMMARY  
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver scientific advice to the 
Commission on the implications for human health of chemically defined flavouring substances used in 
or on foodstuffs in the Member States. In particular, the CEF Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
The previous version of this consideration, FGE.86Rev1, dealt with 34 aliphatic and arylalkyl amines 
and amides which are in the Register and which were evaluated by JECFA at its 65th meeting. The 
Panel concluded that no structurally related substances to support the evaluation in a corresponding 
Flavouring Group Evaluation (FGE) was available. 
Since the publication of FGE.86Rev1, the Industry has informed that four of the substances, [FL-no: 
11.014, 16.049, 16.093 and 16.094], are no longer used as flavouring substances in Europe and will 
therefore not be further considered in this FGE. The present consideration therefore only deals with 30 
flavouring substances. 
In FGE.86Rev1, the Panel agreed with the application of the Procedure as performed by JECFA for 27 
of the 30 substances. For two substances, piperine [FL-no: 14.003] and deca-(2E,4E)-dienoic acid 
isobutyl-amide [FL-no: 16.091], the Panel did not agree with JECFA that appropriate studies are 
available for deriving NOAELs and concluded that additional toxicity data are required for these two 
substances.  
The present revision of FGE.86Rev1 is due to the submission of the requested toxicity data for [FL-
no: 14.003 and 16.091]. Based on the results of two 90-day oral toxicity studies received by EFSA the 
Panel now concludes that these two substances are not of safety concern when used as flavouring 
substances at the estimated levels of exposure based on the MSDI approach.  
For N-isopentylidene isopentylamine [FL-no: 11.017] the Panel concluded that this substance can be 
metabolised to innocuous products and accordingly evaluated along the A-side of the Procedure (while 
JECFA evaluated [FL-no: 11.017] along the B-side). Like JECFA the Panel concluded that [FL-no: 
11.017] is of no safety concern at estimated level of intake, based on the MSDI approach. 
For 18 substances evaluated by JECFA through the Procedure use levels for the EU have been 
provided by the Industry [FL-no: 11.002, 11.004, 11.005, 11.007, 11.015, 11.016, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.052, 16.091 and 16.092]. The mTAMDI 
figures calculated for the substances in structural class I are 340 µg/person per day, except for [FL-no: 
16.092], for which the mTAMDI is 15000 µg/person/day, exceeding the threshold of 1800 
µg/person/day for structural class I. The mTAMDI figures for the structural class II substances range 
from 200 to 340 µg/person/day, except for [FL-no: 14.141] for which the figure is 600 µg/person/day, 
exceeding the threshold of 540 µg/person/day for structural class II. For the two substances [FL-no: 
16.052 and 16.091] in structural class III the mTAMDI is 200 and 1900 µg/person/day, respectively, 
and both exceed the threshold of concern of 90 µg/person/day for structural class III substances. Thus, 
for four substances [FL-no: 14.141, 16.052, 16.091 and 16.092] the intakes, estimated on the basis of 
the mTAMDI approach, exceed the threshold for their structural classes. Therefore more reliable 
exposure data are required. On the basis of such additional data, these flavouring substances should be 
considered using the Procedure. Subsequently, additional data might become necessary. 
For the remaining 12 substances [FL-no: 11.001, 11.003, 11.006, 11.009, 11.017, 14.003, 14.010, 
14.064, 14.167, 16.006, 16.013 and 16.053] use levels are needed to calculate the mTAMDIs in order 
Flavouring Group Evaluation 86 Revision 2
 
EFSA Journal 2015;13(1):3998 3
to identify those flavouring substances that need more refined exposure assessment and to finalise the 
evaluation. 
In order to determine whether the conclusion for the 30 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Specifications 
including complete purity criteria and identity are available for all JECFA evaluated substances.  
Thus, for all 30 JECFA evaluated aliphatic and arylalkyl amines and amides [FL-no: 11.001, 11.002, 
11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 
11.023, 11.025, 11.026, 14.003, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.006, 16.013, 
16.052, 16.053, 16.091 and 16.092] the Panel agreed with JECFA conclusion “no safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA has considered the Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluation 
of aliphatic and aromatic amines and amides in the Flavouring Group Evaluation 86, Revision 1 
(FGE.86Rev1). The opinion was adopted on 25 November 2010. EFSA concluded in its opinion that 
for two substances [FL-no: 14.003 and 16.091] additional toxicity data are still needed before the 
evaluation can be finalised. 
The requested data on piperine [FL-no: 14.003] and deca-(2E,4E)-dienoic acid isobutyl-amide [FL-no: 
16.091] have now been submitted by the applicants.  
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to finalise its safety 
assessment on piperine [FL-no: 14.003] and deca-(2E,4E)-dienoic acid isobutyl-amide [FL-no: 
16.091] in accordance with Commission Regulation (EC) No 1565/2000. 
INTERPRETATION OF TERMS OF REFERENCE 
In the terms of reference as provided by the Commission substances are indicated as Aromatic 
Amines. This description is not appropriate and the Panel will use a description “Arylalkyl Amines” 
instead. 
                                                     
4
  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p.34-50. 
5
  Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1. 
6 
 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of particular importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by JECFA only on the basis of these 
figures. For Register substances for which this is the case the Panel will need EU production figures in 
order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006a). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by JECFA or has 
not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by JECFA. The Panel will need information on use 
levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram per Person per Day (Step B5) Used by JECFA 
JECFA uses the threshold of concern of 1.5 µg/person per day as part of the evaluation procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
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Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of JECFA evaluated substances, the Panel will examine the structural relationship 
and metabolism features of the substances within the flavouring group and compare this with the 
corresponding FGE. 
1. History of the Evaluation of the Substances in the Present FGE  
In FGE.86, which considered 35 aliphatic and arylalkyl amines and amides, the Panel concluded that 
for five substances no applicable NOAEL was available for the substance itself or for a structurally 
related substance and accordingly further data are required. 
The first Revision of Flavouring Group Evaluation 86 (FGE.86Rev1) included a re-consideration of 
three candidate substances [FL-no: 16.091, 16.093 and 16.094] as additional toxicity data had been 
submitted. Furthermore, EU production figures were provided for two substances [FL-no: 11.006 and 
16.053] (EFFA, 2010). Furthermore, additional information on stereoisomeric composition [FL-no: 
16.013], composition of mixture [FL-no: 11.017], specifications (data on solubility [FL-no: 14.064 
and 14.168]) and missing ID-tests [FL-no: 11.017, 14.168 and 16.094] was received (EFFA, 2010) 
after publication of FGE.86 and included in Revision 1. 
2-Propionyl pyrroline [FL-no: 14.168], which contains an α,β-unsaturated ketone structure has been 
withdrawn from FGE.86Rev1 and transferred to FGE.223 for evaluation with respect to a possible 
genotoxic potential. 
FGE Opinion adopted Link No. of substances 
FGE.86 22 May 2008 http://www.efsa.europa.eu/en/efsajournal/pub/745.htm 35 
FGE.86Rev1 25 November 2010 http://www.efsa.europa.eu/en/efsajournal/pub/1926.htm 34 
FGE.86Rev2   30 
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The present revision of FGE.86, FGE.86Rev2, includes evaluation of additional toxicity data provided 
for piperine [FL-no: 14.003] (EFFA, 2013; Bauter, 2013) and deca-(2E,4E)-dienoic acid isobutyl-
amide [FL-no: 16.091] (Flavour Industry, 2013; Koetzner, 2013a; Koetzner, 2013b).  
A search in the open literature did not reveal any pertinent new information. 
Furthermore, the Industry has submitted the requested EU production figures for five substances [FL-
no: 11.006, 14.167, 16.053, 16.091 and 16.092] (EFFA, 2004; Flavour Industry, 2004a, 2004b), and 
new information on the composition of the stereoisomeric mixture for [FL-no: 16.013] (EFFA, 2014). 
These new data have also been included in the present revision of FGE.86. 
Finally, the industry has informed that four substances, N,N-dimethylphenethylamine [FL-no: 11.014], 
butyramide [FL-no: 16.049], N-cyclopropyl (2E,6Z)-nonadienamide [FL-no: 16.093] and N-ethyl 
(2E,6Z)-nonadienamide [FL-no: 16.094] are no longer supported for use as flavouring substances in 
Europe (DG SANCO, 2012) and the substances will therefore not be considered any further. 
2. Presentation of the Substances in JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA Status 
JECFA has evaluated a group of 37 flavouring substances consisting of aliphatic and arylalkyl amines 
and amides at the 65th meeting (JECFA, 2006b). 
2.1.2. EFSA Considerations 
Two of the 37 flavouring substances evaluated by JECFA in the group named “aliphatic and aromatic 
amines and amides” are not in the Register (1-amino-2-propanol and acetamide; JECFA-no: 1591 and 
1592, respectively). A third substance evaluated by JECFA contains an α,β-unsaturated ketone moiety 
and has been considered with respect to genotoxicity in FGE.223, corresponding to subgroup 5.1 of 
FGE.19 (EFSA, 2008a), for which a final conclusion regarding its genotoxic properties could not be 
reached and additional data were requested. Since the publication of FGE.86Rev1, the industry has 
informed that four of the 34 substances are no longer supported for use as flavouring substances in EU 
(DG SANCO, 2012; DG SANCO, 2014). This consideration therefore only deals with 30 flavouring 
substances. 
A summary of the specifications and structural formulas of the 30 substances is given in Table 1. 
2.2. Isomers 
2.2.1. Status 
The following five substances [FL-no: 11.005, 11.020, 14.133, 16.013 and 16.092] in the group of 
JECFA evaluated aliphatic and arylalkyl amines and amides have one or more chiral centres. Two 
substances [FL-no: 14.003 and 16.091] can exist as geometrical isomers. 
2.2.2. EFSA Considerations 
Adequate information on stereoisomeric composition is available for all substances. 
2.3. Specifications 
2.3.1. Status 
JECFA specifications are available for all 30 substances (JECFA, 2005). See Table 1 
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2.3.2. EFSA Considerations 
The available specifications are considered adequate for all substances. 
3. Intake Estimation 
3.1. Status 
For all 30 substances evaluated through JECFA Procedure intake data, based on the MSDI approach, 
are available for the EU. (See Table 5). 
After publication of FGE.86, JECFA has re-evaluated flavouring substances for which updated 
tonnage (production) data were submitted to JECFA by Industry. These updated tonnage figures were 
included for the substances [FL-no: 11.002, 11.004, 11.005, 11.007, 11.015, 11.016, 11.017, 11.018, 
11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049 and 16.052] in FGE.86Rev1. 
Furthermore, the Industry has submitted production figures for the EU for five further substances [FL-
no: 11.006, 14.167, 16.053, 16.091 and 16.092] (EFFA, 2004; Flavour Industry, 2004a, 2004b). These 
figures are included in the present revision of FGE.86. 
3.2. EFSA Considerations 
For 18 substances [FL-no: 11.002, 11.004, 11.005, 11.007, 11.015, 11.016, 11.018, 11.020, 11.021, 
11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.052, 16.091 and 16.092], the Industry has 
submitted food categories7 and use levels in these food categories, for normal and maximum use 
(EFFA, 2005; EFFA, 2007; Flavour Industry, 2004b) (see Table 6, Appendix A). Based on these 
normal use levels mTAMDI figures can be calculated (see Table 7, Appendix A), (EFSA, 2004).  
For the remaining 12 substances [FL-no: 11.001, 11.003, 11.006, 11.009, 11.017, 14.003, 14.010, 
14.064, 14.167, 16.006, 16.013 and 16.053] use levels are needed to calculate the mTAMDIs. 
 
                                                     
7
  Annex III, Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption 
of an evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Summary of Specification Data (JECFA, 2005) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA 
comments/  
Reference for 
specifications 
11.001 
1587 
3-Methylbutylamine 
H2N
 
3219 
512 
107-85-7 
Liquid 
C5H13N 
87.16 
Soluble 
Soluble 
95 - 97 
- 
NMR 
98 % 
1.405 - 1.411 
0.747 - 0.753 
 
 
11.002 
1583 
Isobutylamine 
NH2
 
4239 
513 
78-81-9 
Liquid 
C4H11N 
73.14 
Soluble 
Soluble 
68 
- 
MS 
95 % 
1.391 - 1.397 
0.731 - 0.737 
 
 
11.003 
1582 
Butylamine 
NH2
 
3130 
524 
109-73-9 
Liquid 
C4H11N 
73.14 
Soluble 
Soluble 
78 
- 
NMR 
99 % 
1.398 - 1.404 
0.732 - 0.740 
 
 
11.004 
1580 
Propylamine NH2
 
4237 
601 
107-10-8 
Liquid 
C3H9N 
59.11 
Soluble 
Soluble 
48 
- 
MS 
95 % 
1.384 - 1.390 
0.714 - 0.720 
 
 
11.005 
1584 
sec-Butylamine NH2
 
4240 
707 
13952-84-6 
Liquid 
C4H11N 
73.14 
Soluble 
Soluble 
63 
- 
MS 
95 % 
1.387 - 1.393 
0.715 - 0.721 
Racemate. 
11.006 
1589 
Phenethylamine H2N
 
3220 
708 
64-04-0 
Liquid 
C8H11N 
121.18 
Soluble 
Soluble 
194 - 195 
- 
NMR 
95 % 
1.526 - 1.532 (25°) 
0.961 - 0.967 
 
 
11.007 
1590 
2-(4-Hydroxy-
phenyl)ethylamine 
H2N
OH
 
4215 
709 
51-67-2 
Solid 
C8H11NO 
137.18 
Soluble 
Soluble 
- 
165 
MS 
95 % 
n.a. 
n.a. 
 
 
11.009 
1610 
Trimethylamine 
N
 
3241 
10497 
75-50-3 
Gas 
C3H9N 
59.11 
Soluble 
Soluble 
3 - 4 
- 
NMR 
98 % 
n.a. 
0.667 - 0.675 (4°) 
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Table 1:  Summary of Specification Data (JECFA, 2005) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA 
comments/  
Reference for 
specifications 
11.014 
1613 
N,N-
Dimethylphenethylamine 
N
 
4248 
 
19342-01-9 
Liquid 
C10H15N 
149.24 
Soluble 
Soluble 
183 
- 
MS 
95 % 
1.500 - 1.506 
0.898 - 0.904 
No longer 
supported by 
Industry (DG 
SANCO, 2012).  
11.015 
1579 
Ethylamine NH2
 
4236 
10477 
75-04-7 
Gas 
C2H7N 
45.08 
Soluble 
Soluble 
17 
-81 
MS 
95 % 
n.a. 
0.682 - 0.686 (10°) 
 
11.016 
1588 
Hexylamine H2N
 
4243 
10478 
111-26-2 
Liquid 
C6H15N 
101.19 
Soluble 
Soluble 
130 
- 
MS 
95 % 
1.415 - 1.421 
0.761 - 0.767 
 
 
11.017 
1606 
N-Isopentylidene 
isopentylamine 
N
 
3990 
 
35448-31-8 
Liquid 
C10H21N 
155.29 
Insoluble 
Soluble 
145 - 148 
- 
MS 
98 % 
1.422 - 1.428 
0.768 - 0.774 
 
 
11.018 
1581 
Isopropylamine NH2
 
4238 
10480 
75-31-0 
Liquid 
C3H9N 
59.11 
Soluble 
Soluble 
34 
- 
MS 
95 % 
1.367 - 1.373 
0.687 - 0.693 
 
 
11.020 
1586 
2-Methylbutylamine 
NH2
 
4241 
10484 
96-15-1 
Liquid 
C5H13N 
87.16 
Soluble 
Soluble 
96 
- 
MS 
95 % 
1.417 - 1.423 
0.777 - 0.779 
Racemate. 
11.021 
1585 
Pentylamine H2N
 
4242 
11734 
110-58-7 
Liquid 
C5H13N 
87.16 
Soluble 
Soluble 
103 
- 
MS 
95 % 
1.418 - 1.424 
0.750 - 0.759 
 
 
11.023 
1611 
Triethylamine 
N
 
4246 
10496 
121-44-8 
Liquid 
C6H15N 
101.19 
Soluble 
Soluble 
88 
- 
MS 
95 % 
1.395 - 1.401 
0.724 - 0.730 
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Table 1:  Summary of Specification Data (JECFA, 2005) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA 
comments/  
Reference for 
specifications 
11.025 
1614 
Trimethylamine oxide 
N+ O-
 
4245 
10494 
1184-78-7 
Solid 
C3H9NO 
75.11 
Soluble 
Soluble 
- 
213 
MS 
95 % 
n.a. 
n.a. 
 
 
11.026 
1612 
Tripropylamine 
N
 
4247 
10495 
102-69-2 
Liquid 
C9H21N 
143.27 
Soluble 
Soluble 
156 
- 
MS 
95 % 
1.411 - 1.417 
0.754 - 0.760 
 
 
14.003 
1600 
Piperine 
N
O
O
O
 
2909 
492 
94-62-2 
Solid 
C17H19O3N 
285.34 
Very slightly 
soluble 
Soluble 
- 
128 - 130 
NMR 
97 % 
n.a. 
n.a. 
Register name to 
be changed to 
(E,E)-piperine. 
14.010 
1607 
Piperidine 
N
H
 
2908 
675 
110-89-4 
Liquid 
C5H11N 
85.15 
soluble 
Soluble 
106 
- 
IR 
98 % 
1.450 - 1.454 
0.858 - 0.862 
 
 
14.064 
1609 
Pyrrolidine 
N
H
 
3523 
10491 
123-75-1 
Liquid 
C4H9N 
71.12 
Soluble 
Freely soluble 
87 - 89 
- 
IR NMR 
95 % 
1.440 - 1.446 
0.847 - 0.853 
 
 
14.080 
1604 
2-Acetyl-1-pyrroline 
N
O
 
4249 
 
99583-29-6 
Solid 
C6H9NO 
111.14 
Soluble 
Soluble 
- 
19 
MS 
95 % 
n.a. 
n.a. 
 
 
14.133 
1608 
2-Methylpiperidine HN
 
4244 
 
109-05-7 
Liquid 
C6H13N 
99.18 
Soluble 
Soluble 
118 
- 
MS 
95 % 
1.442 - 1.448 
0.838 - 0.844 
Racemate. 
14.141 
1615 
Piperazine 
HN NH
 
4250 
 
110-85-0 
Solid 
C4H10N2 
86.14 
Soluble 
soluble 
- 
109 
MS 
n.a. 
n.a. 
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Table 1:  Summary of Specification Data (JECFA, 2005) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA 
comments/  
Reference for 
specifications 
95 % 
14.167 
1603 
1-Pyrroline 
N
 
3898 
 
5724-81-2 
Liquid 
C4H7N 
69.10 
Soluble 
Soluble 
87 - 89 
- 
NMR 
99 % 
1.440 - 1.446 
0.849 - 0.855 
 
 
16.006 
1599 
N-Nonanoyl 4-hydroxy-
3-methoxybenzylamide 
HO
O
H
N
O
2787 
590 
2444-46-4 
Solid 
C17H27O3N 
293.41 
Slightly soluble 
Soluble 
- 
124 - 128 
NMR 
96 % 
n.a. 
n.a. 
 
 
16.013 
1601 
N-Ethyl-2-isopropyl-5-
methylcyclohexane 
carboxamide O NH
 
3455 
2298 
39711-79-0 
Solid 
C13H25ON 
211.35 
Insoluble 
Soluble 
- 
91 - 93 
NMR 
98 % 
n.a. 
n.a. 
60 - 90 % (1R, 2S, 
5R) or L- and 5 - 
40 % (1S,2R,5S) 
or D- with minor 
amounts of other 
diastereomers (up 
to 10 %) (EFFA, 
2014). 
16.049 
1593 
Butyramide 
NH2
O
 
4252 
 
541-35-5 
Solid 
C4H9NO 
87.12 
Soluble 
Soluble 
- 
115 
NMR MS 
95 % 
n.a. 
n.a. 
No longer 
supported by 
Industry (DG 
SANCO, 2012). 
16.052 
1594 
1,6-Hexalactam HN
O
 
4235 
 
105-60-2 
Solid 
C6H11NO 
113.16 
Soluble 
Soluble 
- 
70 
NMR MS 
95 % 
n.a. 
n.a. 
 
 
16.053 
1595 
2-Isopropyl- N,2,3-
trimethylbutanamide 
HN
O
 
3804 
10459 
51115-67-4 
Solid 
C10H21ON 
171.28 
insoluble 
Soluble 
- 
56 - 64 
NMR 
99 % 
n.a. 
n.a. 
 
 
16.091 
1598 
Deca-(2E,4E)-dienoic 
acid isobutyl-amide 
N
H
O
 
4148 
 
18836-52-7 
Solid 
C14H25NO 
223.36 
Insoluble 
Soluble 
- 
82 - 90 
IR NMR MS 
95 % 
n.a. 
n.a. 
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Table 1:  Summary of Specification Data (JECFA, 2005) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index (d) 
Spec.gravity (e) 
EFSA 
comments/  
Reference for 
specifications 
16.092 
1602 
N,N-Dimethyl menthyl 
succinamide 
O
O
N
O
 
4230 
 
544714-08-1 
Liquid 
C16H30O2N2 
282.43 
Slightly soluble 
Soluble 
380 
- 
IR NMR 
95 % 
1.522 - 1.530 
0.965 - 0.975 
Register name to 
be changed to 
(1R,2S,5R) N,N-
Dimethyl menthyl 
succinamide. 
16.093 
1597 
N-Cyclopropyl (2E,6Z)-
nonadienamide 
N
H
O
 
4087 
 
608514-55-2 
Solid 
C12H19NO 
193.29 
Sparingly 
soluble 
Soluble 
- 
33 - 37 
IR NMR 
95 % 
n.a. 
n.a. 
No longer 
supported by 
Industry (DG 
SANCO, 2012). 
16.094 
1596 
N-Ethyl (2E,6Z)-
nonadienamide 
N
H
O
 
4113 
 
608514-56-3 
Liquid 
C11H19NO 
181.28 
Sparingly 
soluble 
Soluble 
120 ( 0.8 hPa) 
- 
IR NMR MS 
96 % 
1.484 - 1.493 
0.910 - 0.920 
No longer 
supported by 
Industry (DG 
SANCO, 2014). 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
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4. Genotoxicity Data 
4.1. Genotoxicity Studies – Text Taken8 from JECFA (JECFA, 2006b) 
In vitro 
No mutagenicity was found in the standard Ames assay when various strains of Salmonella 
typhimurium (TA97a, TA98, TA100, TA102, TA1535, TA1537, TA1538, TA1530, TA1531, TA1532 
and TA1964) were incubated with up to 10000 µg/plate of ethylamine [FL-no: 11.015], 
isopropylamine [FL-no: 11.018], butylamine [FL-no: 11.003], isobutylamine [FL-no: 11.002], 
pentylamine [FL-no: 11.021], acetamide (No. 1592, not in Register), 2-isopropyl-N,2,3-
trimethylbutyramide [FL-no: 16.053], deca-(2E,4E)-dienoic acid isobutyl-amide [FL-no: 16.091], 
piperine [FL-no: 14.003], piperidine [FL-no: 14.010], pyrrolidine [FL-no: 14.064], trimethylamine 
[FL-no: 11.009], triethylamine [FL-no: 11.023] or piperazine [FL-no: 14.141] with or without 
metabolic activation (Green and Savage, 1978; Haworth et al., 1978; Andrews et al., 1980; Florin et 
al., 1980; Haworth et al., 1983; Mortelmans et al., 1986; Zeiger et al., 1987; Karekar et al., 1996; 
King, 2003). 
In a host-mediated assay in which S. typhimurium strain TA1950, TA1951, TA1952 or TA1964 was 
injected intraperitoneally into mice followed by an intramuscular injection of 800 mg/kg bw of 
piperidine or pyrrolidine, no mutagenicity was observed (Green and Savage, 1978).  
There was no evidence of DNA damage when Escherichia coli 343/591 uvrB-/recA-/lac+ or 
uvrB+/recA+/lac+ was incubated with up to 1080 mM (63793 µg/ml) of acetamide (No. 1592, not in 
Register) or up to 33.7 mM (2870 µg/ml) of piperidine [FL-no: 14.010] (Hellmér and Bolcsfoldi, 
1992). In the SOS Chromotest with E. coli PQ37, the N-nitroso derivative of tyramine [FL-no: 11.007] 
gave positive results (Ohshima et al., 1989). 
Assays in mammalian cell lines have been performed with tyramine [FL-no: 11.007], acetamide (No. 
1592, not in Register), 2-isopropyl-N,2,3-trimethylbutyramide [FL-no: 16.053], and piperidine [FL-
no: 14.010]. Unscheduled DNA synthesis was not increased when WI-38 human cells were incubated 
with 125 - 2000 µg/ml of 2-isopropyl-N,2,3-trimethylbutyramide (Skinner, 1978). No single-strand 
DNA breaks were reported when 0.03 - 1000 mM (2 - 59068 µg/ml) of acetamide or 0.03 - 3 mM (2.6 
to 255 µg/ml) of piperidine were incubated with rat hepatocytes (Sina et al., 1983). Mixed results have 
been reported with tyramine and piperidine in the mouse lymphoma forward mutation assay: positive 
results were reported for both compounds when tested at up to 823 and 688 µg/ml, respectively, in 
L5178Y mouse lymphoma cells with and without metabolic activation;, but only at cytotoxic doses 
(Wangenheim and Bolcsfoldi, 1988). No mutagenic effects were reported when tyramine and 2-
isopropyl-N,2,3-trimethylbutyramide were tested at concentrations of up to 3500 and 1000 µg/ml, 
respectively, in L5178Y mouse lymphoma cells (Kirby et al., 1978; McGregor et al., 1988). No 
mutagenic effects were observed when piperidine was tested at concentrations of up to 512 µg/ml 
without metabolic activation in L5178Y mouse lymphoma cells; however, equivocal results were 
noted when metabolic activation was added (Garberg et al., 1988). 
In vivo 
In male and female C57BL/6, male CBA, male CD1 and male BDF1 mice, a single dose of acetamide 
(No. 1592, not in Register) of up to 5000 mg/kg bw did not induce micronuclei in the bone marrow or 
peripheral blood when administered by gavage or intraperitoneal injection (Mirkova, 1996; Morita et 
al., 1997). Micronuclei were found in the bone marrow of female C57BL/6 mice given 3.39 mmol/kg 
bw (approximately 200 mg/kg bw) of acetamide by gavage 30 and 6 h before termination; however, 
no dose-response relation was seen, as only a single dose was used (Chieli et al., 1987).  
                                                     
8
 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
 FGE has been removed. 
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Piperine [FL-no: 14.003] did not induce micronuclei in the bone marrow of male Swiss mice given a 
single dose of 10 or 20 mg/kg bw by gavage (Karekar et al., 1996) or two intraperitoneal doses (at 0 
and 24 h) for a total dose of up to 4 mg/kg bw (Muralidhara and Narasimhamurthy, 1990). 
Male and female 1C3F1 mice were given a single dose of 1000 mg/kg bw of 1,6-hexalactam [FL-no: 
16.052] by gavage, and bone marrow was sampled from groups of 10 animals after 24, 30 and 48 h. 
Colchicine was administered to the mice 1 h before sacrifice. No chromosomal aberrations were seen 
(Adler and Ingwersen, 1989). The Comet assay was used to quantify DNA damage in cells from 
organs of male ddy mice given either acetamide (No. 1592, not in Register) or 1,6-hexalactam [FL-no: 
16.052]. No DNA damage was reported in mice given a single dose of 2000 mg/kg bw 1,6-hexalactam 
by gavage; however, DNA damage was reported in the stomach, colon, lungs and bone marrow of 
male mice given a single intraperitoneal injection of acetamide at 2,000 mg/kg bw (Sasaki et al., 
2000). 
1,6-Hexalactam [FL-no: 16.052] did not induce replicative DNA synthesis in rat or mouse hepatocytes 
after treatment in vivo or in vitro at a dose of 350 or 700 mg/kg bw or 250 or 500 mg/kg bw, 
respectively (Uno et al., 1994; Miyagawa et al., 1995). In the mouse spot test, a single [route not stated 
but assumed to be intraperitoneal] injection of 1,6-hexalactam at a dose of up to 500 mg/kg bw 
significantly increased the frequency of spots over those in controls (Neuhäuser-Klaus and 
Lehmacher, 1989); however, statistically significant effects were observed in only one of three or four 
trials. It has been suggested that the colour spots observed were indicative of mitotic recombination 
and not mutation (Fahrig, 1989). Moreover, administration of 700 mg/kg bw in one trial did not 
significantly increase the frequency of spots over that in controls (Neuhäuser-Klaus and Lehmacher, 
1989).  
Female Drosophila melanogaster larvae fed up to 20 mmol/l (2263 µg/ml) of 1,6-hexalactam [FL-no: 
16.052] showed sex-linked recessive lethal mutations and somatic mutation-mitotic recombination, 
whereas male larvae fed up to 5 mmol/l (566 µg/ml) did not have sex-linked recessive lethal mutations 
(Vogel, 1989).  
Piperidine [FL-no: 14.010] and pyrrolidine [FL-no: 14.064] were tested for promoting activity in male 
Wistar rats given a single dose of 100 mg/kg bw of the test substance by gavage in dimethyl 
sulphoxide or 1 % Tylose. The number of mitoses in the adrenal cortex was examined 36 h after 
dosing. Only administration of pyrrolidine in dimethyl sulphoxide caused a statistically significant 
increase (approximately two-fold) in the number of mitoses over that in controls (Danz and Urban, 
1979).  
Piperine [FL-no: 14.003] and piperidine [FL-no: 14.010] did not cause mutations in male germ cells, 
as assessed by sperm shape abnormality and tests for dominant lethal mutations in mice and hamsters. 
Mice given piperine at doses of up to 75 mg/kg bw/day by gavage or up to 4 mg/kg bw per day by 
intraperitoneal injection for 5 days showed no sperm shape abnormalities or dominant lethal mutations 
(Muralidhara and Narasimhamurthy, 1990; Karekar et al., 1996; Daware et al., 2000). In another 
study, an oral dose of 400 mg/kg bw/day of piperidine for 40-100 days did not induce sperm shape 
abnormalities in mice or hamsters (Bempong and Scully, 1983).  
Conclusion on genotoxicity 
Negative results were reported in bacterial assays for reverse mutation with 15 aliphatic and aromatic 
amine and amide derivatives: ethylamine, isopropylamine, butylamine, isobutylamine, sec-butylamine, 
pentylamine, acetamide, 2-isopropyl-N,2,3-trimethylbutyramide, Deca-(2E,4E)-dienoic acid isobutyl-
amide, piperine, piperidine, pyrrolidine, trimethylamine, triethylamine and piperazine.  
Two substances, tyramine and piperidine, gave both positive and negative results in the mouse 
lymphoma assay, particularly at cytotoxic concentrations, while nitrosated tyramine gave positive 
results in the SOS Chromotest with E. coli.  
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Piperine and piperidine consistently gave negative results in a variety of studies in vivo, whereas 
acetamide, 1,6-hexalactam and pyrrolidine gave mainly negative results with some positive findings.  
For a summary of in vitro / in vivo genotoxicity data considered by JECFA, see Table 2. 
4.2. EFSA Considerations 
The only valid positive in vivo genotoxicity studies cited by JECFA are related to acetamide, which 
JECFA considered inappropriate to be used as a flavouring substance due to its reported 
carcinogenicity in both rats and mice, and consequently it was not evaluated using the Procedure.  
N-nonanoyl 4-hydroxy-3-methoxybenzylamide [FL-no: 16.006] (Nonivamide, pelargonyl 
vanillylamide (PAVA)) is structurally related to capsaicin. Capsaicin has been evaluated by SCF in 
2002 (SCF, 2002) and concluded to have shown genotoxic effects in vitro and in vivo and accordingly 
deleted from the Register. However, N-nonanoyl 4-hydroxy-3-methoxybenzylamide has more recently 
been evaluated by the UK Committee on Toxicity of Chemicals in Food in 2004 (COT, 2004) and 
concluded not to be an in vivo mutagen. The Panel agrees with this conclusion made by COT in 2004, 
based on the negative results of a bone marrow cytogenetic assay (COT, 2002) and an in vivo liver 
unscheduled DNA synthesis assay (Clay, 2003). Accordingly N-nonanoyl 4-hydroxy-3-
methoxybenzylamide [FL-no: 16.006] can be evaluated through the Procedure along the B-side, which 
is also done by JECFA. 
For 1,6-hexalactam [FL-no: 16.052] the Panel noted an increased frequency of spots in only one of 
three or four trials in the mouse spot tests. In addition, sex-linked recessive lethal mutations and 
somatic mutations were reported in female Drosophila larvae fed 1,6-hexalactam. However, 1,6-
hexalactam did not show carcinogenic effects in male and female mice and rats following daily 
administration for two years of up to 2250 mg/kg bw (mice) or up to 350 mg/kg bw (rats).  
The Panel agreed with JECFA that the available studies on genotoxicity did not preclude the 
evaluation of the aliphatic and arylalkyl amines and amides by using the Procedure. 
For N-cyclopropyl (2E,6Z)-nonadienamide [former candidate substance FL-no: 16.093, not used as 
flavour in EU any more] additional genotoxicity data have been submitted by EFFA (Bowles, 2003). 
The substance was tested in a bacterial reverse mutation test using S. typhimurium strains TA98, 
TA100, TA1535, 1537 and E. coli strain WP2uvrA with and without metabolic activation (see 
Table 3). It was concluded to be negative regarding the induction of mutagenicity. 
5. New Toxicity Data Considered by the Panel in FGE.86Rev2 
5.1. 90-day Dietary Toxicity Study in Crl:CD (SD) Rats with Piperine [FL-no: 14.003] 
A 90-day study was performed with piperine [FL-no: 14.003] (Bauter, 2013). The study was 
performed according to OECD Guideline (TG 408). Four groups of adult Crl: Sprague-Dawley® CD® 
IGS rats (10/sex/group) were maintained on diets, calculated to provide piperine intake levels of 4.8, 
14.5 and 47.8 mg/kg bw/day in males and 4.8, 14.6 and 48.4 mg/kg bw/day in females, giving an 
average daily intake of 0 (vehicle), 5, 15 or 50 mg/kg bw/day for males and females for at least 
90 days. 
Homogeneity, stability, and concentration analyses of the test diets indicate that piperine was 
homogeneously distributed, stable and was considered to have met target concentrations in the diet for 
all intake levels.  
Prior to study initiation and again on day 86, the eyes of all rats were examined by focal illumination 
and indirect ophthalmoscopy. The animals were observed for viability, signs of gross toxicity, and 
behavioral changes, occurring at least once daily during the study, and weekly for a battery of detailed 
clinical parameters. Body weights were recorded twice during acclimation, including prior to test 
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initiation (day 0), and together with food consumption, approximately weekly thereafter, and prior to 
sacrifice. Urine and blood samples were collected on day 85 from all study animals for urinalysis, 
hematology, and clinical chemistry determinations. Coagulation assessments were performed on day 
92 or 93, prior to necropsy. Gross necropsies and histological evaluation of selected organs and tissues 
were performed on all study animals.  
There were no mortalities, clinical or ophthalmological changes, attributable to piperine 
administration. Decreased male body weight gain (20 % reduction) and male (15 % reduction) and 
female (12 % reduction) food consumption at 50 mg/kg bw/day target dietary intake were considered 
the result of decreased food intake related to administration of high dietary concentrations of piperine 
since there was no effect on food efficiency. No effect was observed on the final body weights.  
There were no gross and microscopic changes or clinical pathology or organ weight changes attributed 
to the administration of piperine. Some statistically significant changes in hematology, coagulation, 
and clinical chemistry parameters were not dose-dependent, small in magnitude and within the range 
of historical values. A statistical significant and dose-dependent increase in cholesterol in males was 
observed at 15 and 50 mg/kg bw/day, with approximately 30 % and 55 %, respectively. No effect on 
cholesterol was observed in females. Similarly, no changes in organ weight or relative organ weight 
were observed in males or females, except for a reduction in relative epididymides weight at 5 and 50 
mg/kg bw/day in males. This change was small and not dose-dependent, and therefore of limited 
toxicological relevance.  
Based on the dose dependent increased in plasma cholesterol levels in males at the mid and high dose, 
the Panel decided that the lowest dose level of 5 mg/kg bw/day should be considered as the NOAEL. 
5.2. 14- and 90-Day Dietary Study in Rats with Deca-(2E,4E)-dienoic acid isobutyl-amide 
[FL-no: 16.091] 
14-day study 
A 14-day dose-range finding GLP study was performed with the candidate substance deca-(2E,4E)-
dienoic acid isobutyl-amide [FL-no:16.091] (Koetzner, 2013b). Five groups of adult Crl: Sprague-
Dawley® CD® IGS rats (5/sex/group) were placed into two control and three test groups. The test 
compound was added to the diet in a 10 % solution of the vehicle (55 % 1,2-propylene glycol, 45 % 
diethyl malonate). The control groups were a basal diet control (no vehicle) as well as a control which 
received the vehicle. The diets were prepared such that the food consumption (based on food intake 
and body weight) resulted in an intake of the candidate substance of 33, 170 and 330 mg/kg bw/day 
for males, and 35, 185 and 380 mg/kg bw/day for females during 14 days, respectively. Based on 
reductions in food consumption and decreases in body weight and body weight gain in the high dose 
group and the absence of such changes in the middle dose group indicates that male and female rats 
can be expected to tolerate a dose level of approximately 170 (males) or 185 (females) mg/kg bw/day 
of deca-(2E,4E)-dienoic acid isobutyl-amide in a study of longer duration. 
90-day study 
A 90-day study was performed with deca-(2E,6Z)-dienoic acid isobutyl-amide [FL-no: 16.091] 
(Koetzner, 2013a). The study was performed according to OECD guideline (TG 408). Five groups of 
adult Crl: Sprague-Dawley® CD® IGS rats (10/sex/group) were placed into two control and three test 
groups. The diets were prepared such that the food consumption (based on food intake and body 
weight) resulted in an intake of the vehicle (55 % 1,2-propylene glycol, 45 % diethyl malonate), of 0 
or 1000 mg/kg bw/day and of the test diets (containing 10 % of the test compound in the vehicle) of 
100, 400 or 1000 mg/kg bw/day, resulting in intake of respectively 10, 40 and 100 mg/kg bw/day of 
the test article, deca-(2E,4E)-dienoic acid isobutyl-amide for males and females during 90 days, based 
on body weight and feed consumption data.  
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Homogeneity, stability, and concentration analyses of the test diets indicate that deca-(2E,4E)-dienoic 
acid isobutyl-amide was homogeneously distributed, stable and was considered to meet target 
concentrations in the diet for all intake levels.  
The animals were examined by focal illumination and indirect ophthalmoscopy prior to initiation and 
again at the end of the study (day 85), observed for viability, signs of gross toxicity and behavioral 
changes at least once daily during the study and weekly for a battery of detailed clinical observations. 
Urine and blood samples were collected on day 90 from all study animals for urinalysis, hematology 
and clinical chemistry determinations and additional blood samples were collected for coagulation 
assessments on Day 95/96, prior to necropsy. Gross necropsies and histological evaluation of selected 
organs and tissues were performed on all study animals. 
There were no mortalities, clinical observations, ophthalmological, clinical pathology, body weight, 
body weight gain, food consumption (males) or food efficiency changes attributable to deca-(2E,4E)-
dienoic acid isobutyl-amide administration. A statistically significant reduction in food consumption 
was observed at the highest dose level, 100 mg/kg bw/day, in females, but not in males. There were no 
macroscopic findings or organ weight changes attributable to the administration of deca-(2E,4E)-
dienoic acid isobutyl-amide. Microscopically, hypertrophy of the acinar cells in the submandibular 
salivary gland was observed in males at 40 mg/kg bw/day (4/10) and 100 mg/kg bw/day (10/10) and in 
females only at 100 mg/kg bw/day (9/10) at 100 mg/kg bw/day. Hypertrophy was characterised 
microscopically by diffuse enlargement of acinar cells with slightly basophilic, stippled cytoplasm. 
The severity was predominantly slight in males at 40 mg/kg bw/day and moderate at 100 mg/kg 
bw/day, indicating a dose-dependent effect. Since the changes in the submandibular salivary glands 
were not observed in the naïve and vehicle control groups in male and female, this effect was 
attributed to the test substance. 
Based on the toxicological endpoints evaluated, the no-adverse-effect level (NOAEL) for 
administration of deca-(2E,4E)-dienoic acid isobutyl-amide in the diet (as a 10 % mixture in vehicle) 
was determined to be 10 mg/kg bw/day for males as indicated by the histological changes in the 
submandibular salivary glands at 40 and 100 mg kg bw day. 
A summary of the toxicity studies is given in Table 4. 
6. Application of the Procedure 
6.1. Application of the Procedure to Aliphatic and Arylalkyl Amines and Amides by JECFA 
(JECFA, 2006b) 
After publication of FGE.86, JECFA has re-evaluated flavouring substances for which estimated 
intake was originally based on anticipated poundage data (JECFA, 2009). New annual production 
volumes were submitted to JECFA by the Flavour Industry for [FL-no: 11.002, 11.004, 11.005, 
11.007, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 
14.141 and 16.052]. JECFA concluded that there was “no safety concern” for these substances. 
No new monograph was prepared, so all text about anticipated poundage in the below text should not 
be taken into account. 
Step 1. 
In applying the Procedure for the safety evaluation to these flavouring substances, the Committee 
assigned 15 substances [FL-no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.009, 11.015, 11.016, 
11.018, 11.020, 11.021, 11.023, 11.025, 11.026 and 16.092] to structural class I, eight flavouring 
substances [FL-no: 11.006, 11.007, 14.010, 14.064, 14.080, 14.133, 14.141 and 14.167] to structural 
class II and the remaining seven flavouring substances [FL-no: 11.017, 14.003, 16.006, 16.013, 
16.052, 16.053 and 16.091] to structural class III.  
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Step 2. 
Twenty-three flavouring substances in this group, namely all those in structural classes I and II [FL-
no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167 and 16.092] are 
predicted to be metabolised to innocuous products. The evaluation of these substances therefore 
proceeded via the A-side of the Procedure.  
For the seven flavouring substances in structural class III, namely the medium chain saturated and 
unsaturated aliphatic and alicyclic amides [FL-no: 11.017, 14.003, 16.006, 16.013, 16.052, 16.053, 
16.091,] limited metabolic data were available, and evaluation of these substances therefore proceeded 
via the B-side of the Procedure. 
Step A3. 
The estimated daily per capita exposures to all 15 flavouring substances in structural class I are below 
the threshold of concern (1800 µg/person/day for class I). Three of these 15 substances [FL-no: 
11.001, 11.003 and 11.009] are reported to be currently used as flavouring substances, and, according 
to the Procedure, the current use and exposure levels of these three substances raise no safety concern. 
The other 12 substances [FL-no: 11.002, 11.004, 11.005, 11.015, 11.016, 11.018, 11.020, 11.021, 
11.023, 11.025, 11.026 and 16.092] are proposed for use as flavouring substances. Although, 
according to the Procedure, the use of these 12 substances raises no safety concern at the exposure 
estimated from anticipated volumes of production, less uncertain estimates are needed. The estimated 
daily per capita exposure to all nine flavouring substances in structural class II is below the threshold 
of concern (540 µg/day). Three of these nine substances [FL-no: 11.006, 14.010 and 14.064] are 
reported to be used as flavouring substances, and, according to the Procedure, their use raises no safety 
concern at current estimated level of exposure. The other five substances [FL-no: 11.007, 14.080, 
14.133, 14.141 and 14.167] are proposed for use as flavouring substances. Although, according to the 
Procedure, use of these six substances raises no safety concern at the exposure levels estimated from 
anticipated volumes of production, less uncertain exposure estimates are needed.  
Step B3. 
The estimated per capita exposures to five of the flavouring substances in structural class III [FL-no: 
11.017, 14.003, 16.006, 16.052 and 16.091] are below the threshold of concern (90 µg/person/day). 
One of these substances [FL-no: 14.003] is reported to be used as a flavouring substance in Europe 
and the USA, one [FL-no: 16.006] is reported to be used in Europe and to be proposed for use in the 
USA, and three [FL-no: 11.017, 16.052 and 16.091] are proposed for use in both regions. For those 
five substances proposed for use in flavours in one or more region [FL-no: 11.017, 14.003, 16.006, 
16.052 and 16.091] less uncertain exposure estimates are needed. In accordance with the Procedure, 
evaluation of these eight flavouring substances proceeded to Step B4.  
The per capita exposures in the USA of the two remaining flavouring substances in structural class III, 
2-isopropyl-N-2,3-trimethylbutyramide ([FL-no: 16.053]; exposure, 1054 µg/day) and N-ethyl-2-
isopropyl-5-methylcyclohexane carboxamide ([FL-no: 16.013]; exposure, 127 µg/day), exceed the 
threshold of concern for their structural class (90 µg/person/day). In accordance with the Procedure, 
data must be available on these substances or closely related substances for a safety evaluation. For 
[FL-no: 16.053], which is proposed for use as a flavouring substance, a less uncertain exposure 
estimate is needed. 
Step B4. 
The No Observed Effect Level (NOEL) of 750 mg/kg bw/day for 1,6-hexalactam [FL-no: 16.052] in a 
90-day feeding study in rats (NTP, 1982) is at least 2.5 × 1010 times higher than the estimated 
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exposure from its proposed use as a flavouring substance in Europe (0.00002 µg/kg bw/day) and in the 
USA (0.00003 µg/kg bw/day).  
The NOEL of 572 mg/kg bw/day for the structurally related substance, N-isobutyl-2,6,8-
decatrienamide [FL-no: 16.121] (Moore, 2002), is applicable to N-ethyl (2E,6Z)-nonadienamide [FL-
no: 16.094]] and deca-(2E,4E)-dienoic acid isobutylamide [FL-no: 16.091], as they follow similar 
pathways of metabolism. This NOEL is 600000 times the estimated exposure to N-ethyl (2E,6Z)-
nonadienamide [FL-no: 16.094] from its proposed use as a flavouring substance in the USA (1 µg/kg 
bw/day) and at least 600000 times the estimated exposure to deca-(2E,4E)-dienoic acid isobutylamide 
[FL-no: 16.091] from its proposed use as flavouring substance in Europe and in the USA (both 
1 µg/kg bw/day).  
The NOEL of 8.4 mg/kg bw/day for N-nonanoyl 4-hydroxy-3-methoxybenzylamide [FL-no: 16.006] 
(Posternak et al., 1969) is more than 70000 times the estimated exposure from its proposed use as a 
flavouring substance in Europe (0.1 µg/kg bw/day) and 8.4 × 106 times that in the USA (0.001 µg/kg 
bw/day). 
The NOEL of 20 mg/kg bw/day for piperine [FL-no: 14.003] (Bhat and Chandrasekhara, 1986) is 
50000 times the estimated exposure to piperine from its reported use as a flavouring substance in 
Europe (0.4 µg/kg bw/day) and 2 × 107 times that in the USA (0.001 µg/kg bw/day).  
The NOEL of 115 mg/kg bw/day for the structurally related substance sec-butylamine [FL-no: 11.005] 
(Gage, 1970) is applicable to N-isopentylidene isopentylamine [FL-no: 11.017] and is at least 5.75 × 
108 times the estimated intake to N-isopentylidene isopentylamine from its proposed use as flavouring 
substance in Europe (0.0001 µg/kg bw/day) and in the USA (0.0002 µg/kg bw/day). 
Consideration of flavour substances with high exposure, evaluated via the B-side of the Procedure 
In accordance with the Procedure, more data on toxicity were considered to evaluate the safety of 2-
isopropyl-N-2,3-trimethylbutyramide [FL-no: 16.053] and N-ethyl-2-isopropyl-5-
methylcyclohexanecarboxamide [FL-no: 16.013], as the estimated exposure levels from proposed use 
[FL-no: 16.053] and reported use [FL-no: 16.013] as flavouring substances were determined to exceed 
the threshold of concern for structural class III (90 µg per person per day). 
The results of three studies in Sprague-Dawley (CD®) rats treated by gavage were available on 2-
isopropyl-N-2,3-trimethylbutanamide [FL-no: 16.053]: a 14-day study in groups of six rats of each sex 
at a dose of 0, 5, 25 or 50 mg/kg bw in corn oil twice daily (Nixon and Alden, 1978); a 14-week study 
in groups of 30 rats of each sex at a dose of 0, 10, 50 or 100 mg/kg bw in corn oil once daily (Pence, 
1980a); and a 14-week study in groups of 30 rats of each sex at a dose of 0, 1, 2, 5, 10 or 50 mg/kg bw 
in corn oil once daily (Cheng, 1982). The studies showed treatment-related hepatic and renal toxicity 
at doses of 10 mg/kg bw and higher. The NOEL was 5 mg/kg bw/day, on the basis of 
histopathological lesions in the kidneys of male rats in the 14-week study (Cheng, 1982). A study of 
reproductive and teratogenic toxicity in rats at a dose of 0, 10, 50 or 100 mg/kg bw showed no 
reproductive effects or foetal abnormalities (Pence, 1980b). The NOEL of 5 mg/kg bw/day is 280 
times the estimated daily exposure to 2-isopropyl-N-2,3-trimethylbutyramide [FL-no: 16.053] when 
used as a flavouring substance in the USA (18 µg/kg bw/day). 
Two studies were conducted on N-ethyl-2-isopropyl-5-methylcyclohexane carboxamide [FL-no: 
16.013] in rat treated by gavage: a 28-day study in groups of six Crj:CD(SD) rats of each sex at a dose 
of 0, 8, 40, 200 or 1000 mg/kg bw/day (Miyata, 1995) and a 22-week study in groups of 15 Sprague-
Dawley (CFY) rats of each sex at a dose of 0, 100, 300 or 725 mg/kg bw/day. Mild toxicity in the liver 
and kidneys was observed at doses of 40 mg/kg bw and above. Two further studies were conducted in 
beagle dogs given gelatine capsules: a 28-day study in groups of one male and one female given a 
dose of 0, 600, 1000 or 1500 mg/kg bw/day and a 52-week study in groups of three animals of each 
sex given a dose of 0, 100, 300 or 1000 mg/kg bw/day (James, 1974). These studies showed mild toxic 
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effects in the liver at all doses. The NOEL of 8 mg/kg bw/day in these studies is 1000000 times the 
estimated daily exposure to N-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide when used as a 
flavouring substance in Europe (0.008 µg/kg bw/day) and 4000 times that in the USA (2 µg/kg 
bw/day). 
The additional toxicity data indicate that 2-isopropyl-N-2,3-trimethylbutanamide [FL-no: 16.053] and 
N-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide [FL-no: 16.013] would not be expected to 
raise safety concerns at their estimated levels of exposure when used as flavouring substances. For one 
of these substances [FL-no: 16.053], however, less uncertain exposure estimates are needed, as the 
existing estimate was based on anticipated poundage. 
In conclusion, JECFA evaluated all 30 substances as to be of no safety concern at the estimated levels 
of intake as flavouring substances based on the MSDI approach. 
The evaluations of the aliphatic and arylalkyl amines and amides are summarised in Table 6: 
Summary of Safety Evaluation by JECFA (JECFA, 2006b). 
6.2. EFSA Considerations 
After the publication of FGE.86 Industry has submitted additional data (toxicity data and mutagenicity 
data) on substance [FL-no: 16.095] (evaluated in FGE.94 (EFSA CEF Panel, 2010)) to support the 
evaluation of [FL-no: 16.091]. However, the Panel consider the substance [FL no: 16.095] not to be 
sufficiently structurally related to the candidate substance [FL-no: 16.091] owing to no cyclopropyl 
group in [FL-no: 16.091]. Due to the structural difference, routes of metabolism will also be different 
and also difference in toxicity must be anticipated. 
The Panel agrees with the application of the Procedure as performed by JECFA for 27 of the 30 
substances in the group.  
N-isopentylidene isopentylamine [FL-no: 11.017] is anticipated to be completely hydrolysed to 
isopentylamine and isopentylaldehyde, which are further metabolised to innocuous products. 
Accordingly [FL-no: 11.017] can be anticipated to be metabolised to innocuous products and 
evaluated along the A-side of the Procedure. JECFA evaluated [FL-no: 11.017] along the B-side. As 
the estimated European per capita intake of 0.0073 µg is below the threshold of concern for structural 
class III substances of 90 µg/person/day, the Panel concluded (as did JECFA) that there was no safety 
concern of the estimated level of intake of [FL-no: 11.017] based on the MSDI approach. 
For piperine [FL-no: 14.003], JECFA derives a NOAEL of 20 mg/kg bw/day from a 56-day feeding 
study, in which groups of six rats were given different doses of black pepper or oleoresin 
corresponding to up to approximately 20 mg/kg bw/day or 100 mg piperine/kg feed corresponding to 
up to approximately 10 mg/kg bw/day. No histopathology was performed. The Panel did not agree 
with JECFA that the study is appropriate for deriving a NOAEL to be used at step B4 of the Procedure 
for piperine [FL-no: 14.003], and accordingly additional data were required. In response to this data 
request the Flavour Industry submitted a 90-day oral toxicity study in rats (summarised in Section 5.1) 
with piperine [FL-no: 14.003]. Based on this new study the Panel could derive a NOAEL of 5 mg/kg 
bw/day. When the exposure estimate for [FL-no: 14.003], based on MSDI approach, of 6.2 µg per 
capita per day is compared to the NOAEL for [FL-no: 14.003], an adequate margin of safety of more 
than 4.8 × 104 can be calculated for piperine. 
For deca-(2E,4E)-dienoic acid isobutyl-amide [FL-no: 16.091] JECFA makes use of a NOAEL 
derived from a structurally related substance. A NOAEL of 572 mg/kg bw/day for N-isobutyl-2,6,8-
decatrienamide [FL-no: 16.121] has been derived from a 28-day feeding study with groups of 10 rats 
given different amounts of an extract of unknown purity from gold root (Halopsis longiper) with an 
estimated concentration of 50 % of N-isobutyl-2,6,8-decatrienamide (Moore, 2002). This study is also 
considered in FGE.303, in which N-isobutyl-2,6,8-decatrienamide [FL-no: 16.121] is the candidate 
substance. The Panel did not agree with JECFA that the study is appropriate for deriving a NOAEL to 
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be used at step B4 of the Procedure for the substance [FL-no: 16.091], and accordingly additional data 
are required. In response to this request expressed in FGE.86, the Flavour Industry has now submitted 
a palatability and range-finding 14-day study and a 90-day oral toxicity study in rats (the 90-day 
toxicity study is summarised in Section 5.2) with substance [FL-no: 16.091]. Based on this new study 
the Panel could derive a NOAEL of 10 mg/kg bw/day. When the exposure estimate for [FL-no: 
16.091], based on MSDI approach, of 11 µg per capita per day is compared to the NOAEL for [FL-
no: 16.091], an adequate margin of safety of more than 5.5 × 104 can be calculated for deca-(2E,4E)-
dienoic acid isobutyl-amide. 
The Panel considered further the possible consequences of nitrosation after ingestion of the secondary 
and tertiary amine and secondary amide candidate substances according to the approach described in 
the Annex to the minutes of the 30th AFC Panel meeting, May 2008 (EFSA, 2008b). From these 
considerations, the Panel concluded that extremely large margins of exposure could be calculated 
(>> 109) for nitrosated products possibly formed from amines used as flavouring substances in foods. 
Such large margins of exposure indicate that a risk of carcinogenicity resulting from such possible 
nitrosation products is virtually absent. 
The Panel also noted that this conclusion is not applicable for foods preserved with nitrites, because 
for such foods the conditions for nitrosation, either in the foods themselves or after consumption in the 
stomach may differ substantially from the worst-case conditions on which the calculations in the 
above mentioned Annex were based. 
CONCLUSION 
The Panel has considered 30 out of the 37 substances in JECFA flavouring group of aliphatic and 
arylalkyl amines and amides.  
Two of the 37 substances, (1-amino-2-propanol and acetamide; JECFA-no: 1591 and 1592, 
respectively), evaluated by JECFA in this group are not used as flavouring substances in EU and are 
therefore not included in the Register and accordingly not in the Union List. A third substance 
evaluated by JECFA is an α,β-unsaturated ketone [FL-no: 14.168] considered with respect to 
genotoxicity in FGE.223, corresponding to subgroup 5.1 of FGE.19, for which a final conclusion 
regarding its genotoxic properties could not be reached and additional data were requested. Since the 
publication of FGE.86Rev1, the Industry has informed that four substances are no longer used as 
flavouring substances in the EU. This consideration therefore only deals with 30 flavouring 
substances. 
This revision of FGE.86 is made because additional toxicity data, which were requested in previous 
opinions, have now been provided for piperine [FL-no: 14.003] and deca-(2E,4E)-dienoic acid 
isobutyl-amide [FL-no: 16.091]. 
In previous versions of FGE.86 the Panel agreed with the application of the Procedure as performed 
by JECFA for 27 of the 30 substances. For N-isopentylidene isopentylamine [FL-no: 11.017] the Panel 
concluded that this substance can be metabolised to innocuous products and accordingly evaluated 
along the A-side of the Procedure to be of no safety concern at step A3 (while JECFA evaluated [FL-
no: 11.017] along the B-side). For two substances [FL-no: 14.003 and 16.091] the Panel concluded 
that no appropriate studies are available for deriving NOAELs to provide an adequate margin of 
safety. Therefore, the Panel concluded that in FGE.86 additional toxicity data are required for these 
two substances.  
Since the publication of FGE.86Rev1, two 90-day oral toxicity studies have become available for 
piperine [FL-no: 14.003] and deca-(2E,4E)-dienoic acid isobutyl-amide [FL-no: 16.091]. From these 
studies the Panel could derive NOAELs which can provide adequate margins of safety for these two 
substances at the estimated levels of exposure based on the MSDI approach.. 
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For 18 substances [FL-no: 11.002, 11.004, 11.005, 11.007, 11.015, 11.016, 11.018, 11.020, 11.021, 
11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.052, 16.091 and 16.092], food categories and use 
levels in these has been provided by the Industry. Based on these use levels, mTAMDI figures could 
be calculated. For one substance ([FL-no: 16.092] from structural class I the mTAMDI of 15000 
µg/person/day exceeds the threshold for the structural class of 1800 µg/person/day. Also for one 
substance ([FL-no: 14.141] in structural class II the mTAMDI of 600 µg/person/day exceeds the 
threshold for the structural class of 540 µg/person/day and finally two substances [FL-no: 16.052 and 
16.091] in structural class III exceed the threshold of the structural class of 90 µg/person/day with 
mTAMDI figures of 200 and 770 µg/person/day, respectively. Thus, for these four substances, [FL-no: 
14.141, 16.052, 16.091 and 16.092], more reliable exposure data are required. On the basis of such 
additional data, these flavouring substances should be considered using the Procedure. Subsequently, 
additional data might become necessary. 
For the remaining 12 substances [FL-no: 11.001, 11.003, 11.006, 11.009, 11.017, 14.003, 14.010, 
14.064, 14.167, 16.006, 16.013 and 16.053] use levels are needed to calculate the mTAMDIs in order 
to identify those flavouring substances that need more refined exposure assessment and to finalise the 
evaluation. 
In order to determine whether the conclusion for JECFA evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Specifications including 
complete purity criteria and identity are available for all JECFA evaluated substances.  
In conclusion, for all JECFA evaluated aliphatic and arylalkyl amines and amides [FL-no: 11.001, 
11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.017, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.003, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.006, 
16.013, 16.052, 16.053, 16.091 and 16.092] the Panel agrees with JECFA conclusion “no safety 
concern at estimated levels of intake based on the MSDI approach”. 
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SUMMARY OF GENOTOXICITY DATA  
Table 2:  Genotoxicity Data (In Vitro / In Vivo) evaluated by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
In Vitro 
11.015 
1579 
Ethylamine Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, TA1537 
100 to 10000 µg/plate Negative1 Mortelmans et al., 1986 
11.018 
1581 
Isopropylamine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
10 to 10000 µg/plate Negative1 Zeiger et al., 1987 
11.003 
1582 
Butylamine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
3.3 to 3333 µg/plate Negative1 Zeiger et al., 1987 
Reverse Mutation S.typhimurium TA100 3 µmol/plate (219 µg/plate)2 Negative1 Florin et al., 1980 
11.002 
1583 
Isobutylamine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
33 to 10000 µg/plate Negative1 Mortelmans et al., 1986 
11.005 
1584 
sec-Butylamine  Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
10 to 3333 µg/plate Negative1 Zeiger et al., 1987 
11.021 
1585 
Pentylamine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
33 to 3333 µg/plate Negative1 Mortelmans et al., 1986 
11.007 
1590 
2-(4-Hydroxy-
phenyl)ethylamine 
 
Forward Mutation Mouse lymphoma L5178Y 
cells 
500 to 3500 µg/ml Negative McGregor et al., 1988 
Forward Mutation Mouse lymphoma L5178Y 
cells 
0.08, 0.80, 2.0, 4.0 or 6.0 mM 
(11, 109, 274, 548 and 823 µg/ml)3,4 
Positive 5,6 Wangenheim and 
Bolcsfoldi, 1988 
Forward Mutation Mouse lymphoma L5178Y 
cells 
0.40, 0.80, 1.60, 2.39 or 3.20 mM 
(55, 109, 220, 327 and 439 µg/ml)3,4 
Positive 6,7 Wangenheim and 
Bolcsfoldi, 1988 
- 
1592 
Acetamide (not in Register) Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
100 to 10000 µg/plate Negative1 Haworth et al., 1983 
DNA Repair Escherichia coli 343/591 
uvrB-/recA-/lac+ and 
uvrB+/recA+/lac+ 
Up to 1,080 mM (63793 µg/ml)8 Negative1 Hellmér and Bolcsfoldi, 
1992 
Single Strand DNA Breaks Rat hepatocytes 0.03, 0.3, 3, 10, 30, 100, 300 or 1000 
mM (2, 18, 177, 591, 1772, 5907, 
17720 or 59068 µg/ml)8 
Negative Sina et al., 1983 
16.053 2-Isopropyl- N,2,3- Reverse Mutation S.typhimurium TA98, 200, 1000, 5000, 10000, or 20000 Negative1 Haworth et al., 1978 
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Table 2:  Genotoxicity Data (In Vitro / In Vivo) evaluated by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
1595 trimethylbutanamide  TA100, TA1535, TA1537, 
TA1538 
µg/plate  
Forward Mutation Mouse lymphoma L5178Y 
cells 
0.01 to 1000 µg/ml Negative1 Kirby et al., 1978 
 
Unscheduled DNA 
Synthesis 
WI-38 cells (human) 125 to 2000 µg/ml9 Negative1 Skinner, 1978 
 
16.091 
1598 
Deca-(2E,4E)-dienoic acid 
isobutyl-amide 
Reverse Mutation S.typhimurium TA98, 
TA100, TA102, TA1535, 
TA1537 
5 to 1500 µg/plate10 Negative5 King, 2003 
 
Reverse Mutation S.typhimurium TA98, 
TA100, TA102, TA1535, 
TA1537 
5 to 5000 µg/plate11 Negative7 King, 2003 
 
14.003 
1600 
Piperine Reverse Mutation S.typhimurium TA97a, 
TA98, TA100, TA102 
0.01, 0.5, or 10 µmol/plate (3, 143 
and 2853 µg/plate)12 
Negative1 Karekar et al., 1996 
Reverse Mutation (pre-
incubation) 
S.typhimurium TA97a, 
TA98, TA100, TA102 
0.005, 0.05, 0.5 or 5 µmol/plate (1, 
14, 143 and 1427 µg/plate)12,13 
Negative1 Karekar et al., 1996 
Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
1,000 µg Negative1 Andrews et al., 1980 
14.010 
1607 
Piperidine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate (255 µg/plate)14 Negative1 Florin et al., 1980 
Reverse Mutation S.typhimurium TA1530, 
TA1531, TA1532, TA1964 
1 to 5 mg/plate (1,000 to 5,000 
µg/plate)14 
Negative Green and Savage, 1978 
Reverse Mutation 
(microsomal assay) 
S.typhimurium TA1530, 
TA1531, TA1532, TA1964 
0.15 M (12772 µg/ml)14,15 Negative Green and Savage, 1978 
Reverse Mutation (host-
mediated, mice) 
S.typhimurium TA1950, 
TA1951, TA1952, TA1964 
800 mg/kg bw16 Negative Green and Savage, 1978 
Forward Mutation Mouse lymphoma L5178Y 
cells 
3.03, 4.04, 5.05, 6.06 or 7.07 mM 
(258, 344, 430, 516 and 602 µg/ml)14 
Positive 5,6 Wangenheim and 
Bolcsfoldi, 1988 
Forward Mutation Mouse lymphoma L5178Y 
cells 
4.04, 5.05, 6.06, 7.07 or 8.08 mM 
(344, 430, 516, 602 or 688 µg/ml)14 
Negative7 Wangenheim and 
Bolcsfoldi, 1988 
Forward Mutation Mouse lymphoma L5178Y 2.0, 4.01 or 6.01 mM Negative5 Garberg et al., 1988 
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Table 2:  Genotoxicity Data (In Vitro / In Vivo) evaluated by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
cells (170, 341 or 512 µg/ml)14 
Forward Mutation Mouse lymphoma L5178Y 
cells 
2.0, 4.01, 6.01 or 8.02 mM 
(170, 341, 512 or 683 µg/ml)14 
 Equivocal 7,17 Garberg et al., 1988 
DNA Repair Escherichia coli 343/591 
uvrB-/recA-/lac+ and 
uvrB+/recA+/lac+ 
33.7 mM (2870 µg/ml)14,18 Negative5 Hellmér and Bolcsfoldi, 
1992 
DNA Repair Escherichia coli 343/591 
uvrB-/recA-/lac+ and 
uvrB+/recA+/lac+ 
101 mM (8600 µg/ml)14,18 Negative5 Hellmér and Bolcsfoldi, 
1992 
Single Strand DNA Breaks Rat hepatocytes 0.03, 0.3 or 3 mM 
(2.6, 26 and 255 µg/ml)14 
Negative Sina et al., 1983 
14.064 
1609 
Pyrrolidine 
 
Reverse Mutation S.typhimurium TA100 Up to 3 µmol/plate 
(213 µg/plate)19 
Negative1 Florin et al., 1980 
Reverse Mutation S.typhimurium TA1530, 
TA1531, TA1532, TA1964 
1000 to 5000 µg/plate3 Negative Green and Savage, 1978 
Reverse Mutation 
(microsomal assay) 
S.typhimurium TA1530, 
TA1531, TA1532, TA1964 
0.5 M (35561 µg/ml)19 Negative Green and Savage, 1978 
Reverse Mutation (host-
mediated, mice) 
S.typhimurium TA1950, 
TA1951, TA1952, TA1964 
800 mg/kg bw16 Negative Green and Savage, 1978 
11.009 
1610 
Trimethylamine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
10 to 1000 µg/plate Negative1 Mortelmans et al., 1986 
11.023 
1611 
Triethylamine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
10 to 10000 µg/plate Negative1 Zeiger et al., 1987 
14.141 
1615 
Piperazine Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
33 to 3167 µg/plate Negative1 Haworth et al., 1983 
In Vivo 
- 
1592 
Acetamide (not in Register) 
 
DNA Damage (Comet 
assay) 
Male ddy mice 2000 mg/kg bw20 Positive 21 Sasaki et al., 2000 
Micronuclei (bone 
marrow) 
C57B1/6 mice 2500 or 5000 mg/kg bw22 Negative Mirkova, 1996 
Micronuclei (bone Male CBA mice 5000 mg/kg bw22 Negative Mirkova, 1996 
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Table 2:  Genotoxicity Data (In Vitro / In Vivo) evaluated by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
marrow) 
Micronuclei (bone marrow 
and peripheral blood) 
Male CD1 mice 500 to 5000 mg/kg bw23 Negative Morita et al., 1997 
Micronuclei (bone marrow 
and peripheral blood) 
Male BDF1 mice 1250 to 5000 mg/kg bw23 Negative Morita et al., 1997 
Micronuclei (bone 
marrow) 
Female C57B1/6 mice 3.39 mmol/kg bw 
(200 mg/kg bw)24,25 
Positive Chieli et al., 1987 
16.052 
1594 
1,6-Hexalactam 
 
DNA Damage (Comet 
assay) 
Male ddy mice  2000 mg/kg bw22 Negative Sasaki et al., 2000 
Replicative DNA 
Synthesis 
Male F344 rats 350 or 700 mg/kg bw26 Negative Uno et al., 1994 
Replicative DNA 
Synthesis 
Male B6C3F1 mice 250 or 500 mg/kg bw22 Negative Miyagawa et al., 1995 
Mammalian Spot (C57B1xT)F1 mouse 
embryos 
400 or 500 mg/kg bw22 Positive 27 Fahrig, 1989 
Mammalian Spot (TxHT)F1 mouse embryos 500 mg/kg bw28 Positive 29 Neuhäuser-Klaus and 
Lehmacher, 1989 
Mammalian Spot (TxHT)F1 mouse embryos 700 mg/kg bw28 Negative Neuhäuser-Klaus and 
Lehmacher, 1989 
Sex-Linked Recessive 
Lethals 
Male Drosophila 
melanogaster larvae 
5.0 mM30 (566 µg/ml)31 Negative Vogel, 1989 
Sex-Linked Recessive 
Lethals 
Female Drosophila 
melanogaster larvae 
5.0 or 20.0 mM30 
(566 or 2263 µg/ml)31 
Positive Vogel, 1989 
Somatic Mutation/Mitotic 
Recombination 
Female Drosophila 
melanogaster larvae 
2.5, 5.0, 10.0 or 20.0 mM40  
(283, 566, 1132 and 2263 µg/ml)31 
Positive Vogel, 1989 
Chromosomal Aberrations 
(bone marrow) 
Male and female 1C3F1 
mice 
1000 mg/kg bw22 Negative  Adler and Ingwersen, 
1989 
14.003 
1600 
Piperine 
 
Micronuclei (bone 
marrow) 
Male Swiss mice 10 or 20 mg/kg bw22 Negative Karekar et al., 1996 
Micronuclei (bone 
marrow) 
Male Swiss mice 1, 2 or 4 mg/kg bw32 Negative Muralidhara and 
Narasimhamurthy, 1990 
Flavouring Group Evaluation 86 Revision 2
 
EFSA Journal 2015;13(1):3998 29 
Table 2:  Genotoxicity Data (In Vitro / In Vivo) evaluated by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference 
Sperm Morphology Male Swiss mice 10 or 50 mg/kg bw/day33 Negative Karekar et al., 1996 
Sperm Morphology Male Swiss mice 35, 50 or 75 mg/kg bw/day34 Negative Daware et al., 2000 
Sperm Morphology Male Swiss mice 1, 2 or 4 mg/kg bw/day35 Negative Muralidhara and 
Narasimhamurthy, 1990 
Dominant Lethal 
Mutations 
Male and Female Swiss 
mice 
10 or 50 mg/kg bw22 Negative Karekar et al., 1996 
Dominant Lethal 
Mutations 
Male Swiss mice 4 mg/kg bw/day35 Negative Muralidhara and 
Narasimhamurthy, 1990 
14.010 
1607 
Piperidine 
 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in DMSO22 Negative Danz and Urban, 1979 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in 1 % Tylose22 Negative Danz and Urban, 1979 
Sperm Morphology Male hybrid mice 400 mg/kg bw/day36 Negative Bempong and Scully, 
1983 
Sperm Morphology Male golden Syrian 
hamsters 
400 mg/kg bw/day36 Negative Bempong and Scully, 
1983 
14.064 
1609 
Pyrrolidine 
 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in 1 % Tylose22 Negative Danz and Urban, 1979 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in DMSO22 Positive Danz and Urban, 1979 
1 With and without S9. 
2 Calculated using the molecular weight of butrylamine (73.14 g/mol). 
3 Calculated using the molecular weight of tyramine (137.18 g/mol). 
4 Actual compound used in this study was tyramine hydrochloride at concentrations of 0.101 to 7.59 mM (18 to 1318 µg/ml) without metabolic activation, and 0.506 to 4.05 mM (88 to 703 
µg/ml) with metabolic activation. 
5
 Without metabolic activation. 
6
 Significant increases in mutation frequency were observed only at cytotoxic doses. 
7
 With metabolic activation. 
8
 Calculated using the molecular weight of acetamide (59.07 g/mol). 
9
 Cytotoxic at 2000 µg/ml. 
10
 Toxic and precipitates at 1,500 µg/plate. 
11
 Toxic and precipitates at 5,000 µg/plate. 
12
 Calculated using the molecular weight of piperine (285.34 g/mol). 
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13
 Toxic at 5 µmol/plate without metabolic activation. 
14 Calculated using the molecular weight of piperidine (85.15 g/mol). 
15
 Highest non-cytotoxic concentration. 
16
 Intraperitoneal injection of S. typhimurium strain with intramuscular injection of test material. 
17
 Results observed did not meet the criteria for positive or negative classification. 
18
 Concentration at which a significant reduction in the number of colonies of each strain was observed; however, the highest concentration of piperidine tested was 1,010 mM. 
19
 Calculated using the molecular weight of pyrrolidine (71.12 g/mol). 
20
 Administered via a single intraperitoneal injection. 
21
 Increase in DNA damage was observed in the stomach, colon, lungs and bone marrow of mice. 
22
 Administered via a single gavage dose. 
23
 Single, double, or quadruple intraperitoneal injections, separated by 24 hours, were administered. 
24 Administered by gavage at 30 and 6 hours prior to sacrifice. 
25
 Calculated using the molecular weight of acetamide (59.07 g/mol). 
26
 Administered via a single subcutaneous injection. 
27
 Frequency of spots of genetic relevance was significantly increased relative to controls only in 1 out of 3 trials, and only at the highest dose (500 mg/kg bw). 
28
 Administered at a single dose (route not specified). 
29
 Significant increase in spots of genetic relevance was observed only in 1 out of 4 groups receiving 500 mg/kg body weight. 
30 Administered in the diet. 
31
 Calculated using the molecular weight of 1,6-hexalactam (113.16 g/mol). 
32
 Intraperitoneal injection in 2 instalments at 0 and 24 hours. 
33
 Administered via gavage for 5 days. 
34
 Administered orally for 5 consecutive days. 
35
 Administered intraperitoneally for 5 days, followed by a 35-day maintenance period. 
36
 Piperidine was administered orally to mice for 100 days. However, on day 40 and every subsequent 5 days, 3 mice were killed for examination of sperm morphology. 
 
Table 3:  Additional In Vitro Genotoxicity Data Considered by the Panel in FGE.86Rev1  
FL-no 
JECFA-no 
EU Register name 
JECFA name 
End-point Test system Concentration Results Reference Comments 
16.093 
1597 
N-Cyclopropyl (2E,6Z)-
nonadienamide 
Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, TA1537 
Up to 5000 µg/plate Negative1 Bowles, 2003  
Reverse Mutation E.coli WP2 uvrA- Up to 5000 µg/plate Negative1 
16.095 
1779 
N-3,7-Dimethyl-2,6-octadienyl 
cyclopropylcarboxamide 
Reverse Mutation S.typhimurium TA97a, 
TA1535 
Up to 2000 µg/plate Negative Next Century 
Incorporated, 
2004 
Cytotoxic at 
different 
concentration 
with and without 
S9 
Reverse Mutation S.typhimurium TA98, 
TA100 
Up to 5000 µg/plate Negative 
Reverse Mutation Escherichia coli WP2 uvrA 
(328) 
Up to 2000 µg/plate Negative 
1
 With and without S9. 
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SUMMARY OF TOXICITY DATA 
Table 4:  Toxicity Data Considered by the Panel in FGE.86Rev2 
Chemical Name  
[FL-no] 
Species; Sex 
No/group 
Route  Doses 
(mg/kg bw/day) 
Duration 
(days) 
NOAEL 
(mg/kg bw/day) 
Reference  Comments 
Deca-(2E,4E)-dienoic acid isobutyl-amide 
[16.091] 
Rat; M, F  
5 
Diet 0, 333 (350), 1686 (1858) 
and 3271 (3782)  
14 Range-finding Koetzner, 2013b  
Rat; M, F  
10 
Diet 0, 10, 40 and 100  90 10 Koetzner, 2013a  
Piperine [14.003] Rat; M, F  
10 
Diet 0, 5, 15 and 50 90 5 Bauter, 2013  
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SUMMARY OF SAFETY EVALUATIONS 
Table 5:  Summary of Safety Evaluation by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita/day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound (d),(e) 
EFSA conclusion on 
the named 
compound(f) 
EFSA conclusion 
on the material of 
commerce 
11.001 
1587 
3-Methylbutylamine 
H2N
 
24 
0.07 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.002 
1583 
Isobutylamine 
NH2
 
0.012 
0.09 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.003 
1582 
Butylamine NH2
 
89 
0.01 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.004 
1580 
Propylamine NH2
 
0.012 
0.02 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.005 
1584 
sec-Butylamine NH2
 
0.012 
2 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Racemate. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.009 
1610 
Trimethylamine 
N
 
130 
70 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.015 
1579 
Ethylamine NH2
 
0.012 
0.2 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.016 Hexylamine H2N
 
0.024 Class I (d) No safety concern at No safety concern at 
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Table 5:  Summary of Safety Evaluation by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita/day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound (d),(e) 
EFSA conclusion on 
the named 
compound(f) 
EFSA conclusion 
on the material of 
commerce 
1588 0.007 A3: Intake below threshold the estimated level of 
intake based on the 
MSDI approach. 
the estimated level 
of intake based on 
the MSDI approach. 
11.018 
1581 
Isopropylamine NH2
 
0.012 
0.02 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.020 
1586 
2-Methylbutylamine NH2
 
0.012 
0.02 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Racemate. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.021 
1585 
Pentylamine H2N
 
0.037 
0.2 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.023 
1611 
Triethylamine 
N
 
0.073 
0.9 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.025 
1614 
Trimethylamine oxide 
N+ O-
 
2.3 
0.09 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.026 
1612 
Tripropylamine 
N
 
0.012 
0.02 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.092 
1602 
N,N-Dimethyl 
menthyl succinamide 
O
O
N
O
 
61 
88 
Class I 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
Register name to to 
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Table 5:  Summary of Safety Evaluation by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita/day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound (d),(e) 
EFSA conclusion on 
the named 
compound(f) 
EFSA conclusion 
on the material of 
commerce 
be changed to 
(1R,2S,5R)- N,N-
Dimethyl menthyl 
succinamide. 
11.006 
1589 
Phenethylamine H2N
 
0.075 
0.05 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.007 
1590 
2-(4-Hydroxy-
phenyl)ethylamine 
H2N
OH
 
0.012 
0.02 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
14.010 
1607 
Piperidine 
N
H
 
88 
96 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
14.064 
1609 
Pyrrolidine 
N
H
 
0.12 
2 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
14.080 
1604 
2-Acetyl-1-pyrroline 
N
O
 
0.012 
0.1 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
14.133 
1608 
2-Methylpiperidine HN
 
0.012 
0.002 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Racemate. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
14.141 
1615 
Piperazine 
HN NH
 
0.012 
0.002 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
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Table 5:  Summary of Safety Evaluation by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita/day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound (d),(e) 
EFSA conclusion on 
the named 
compound(f) 
EFSA conclusion 
on the material of 
commerce 
14.167 
1603 
1-Pyrroline 
N
 
0.012 
0.4 
Class II 
A3: Intake below threshold 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.049 
1593 
Butyramide 
NH2
O
 
0.012 
0.002 
Class II 
A3: Intake below threshold 
(d) The Panel concluded 
that the substance 
cannot be evaluated 
through the Procedure 
due to concern with 
respect to 
genotoxicity/carcinog
enicity. 
No longer supported 
by Industry (DG 
SANCO, 2012). 
16.013 
1601 
N-Ethyl-2-isopropyl-
5-methylcyclohexane 
carboxamide 
O NH
 
0.4 
127 
Class III 
B3: Intake above threshold 
Data must be 
available (e) 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Toxicity data 
available to establish 
an adequate NOAEL. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.053 
1595 
2-Isopropyl- N,2,3-
trimethylbutanamide 
HN
O
 
24 
1054 
Class III 
B3: Intake above threshold 
Data must be 
available (e) 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Toxicity data 
available to establish 
an adequate NOAEL. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
11.014 
1613 
N,N-Dimethyl-
phenethylamine N
 
0.012 
0.09 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) Toxicity data 
required. 
No longer supported 
by Industry (DG 
SANCO, 2012).  
11.017 
1606 
N-Isopentylidene 
isopentylamine 
N
 
0.012 
0.01 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) EFSA concluded at 
step A3: No safety 
concern at the 
estimated level of 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
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Table 5:  Summary of Safety Evaluation by JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI(a)  
US MSDI 
(µg/capita/day) 
Class(b) 
Evaluation procedure 
path(c) 
Outcome on 
the named 
compound (d),(e) 
EFSA conclusion on 
the named 
compound(f) 
EFSA conclusion 
on the material of 
commerce 
intake based on the 
MSDI approach. 
14.003 
1600 
Piperine 
N
O
O
O
 
6.2 
0.07 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Toxicity data 
available to establish 
an adequate NOAEL. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
CASrn in the 
Register refers to 
the trans,trans 
isomer. 
16.006 
1599 
N-Nonanoyl 4-
hydroxy-3-
methoxybenzylamide 
HO
O
H
N
O
6.0 
0.07 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.052 
1594 
1,6-Hexalactam HN
O
 
0.012 
0.002 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.091 
1598 
Deca-(2E,4E)-dienoic 
acid isobutyl-amide N
H
O 11 
83 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Toxicity data 
available to establish 
an adequate NOAEL. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.093 
1597 
N-Cyclopropyl 
(2E,6Z)-
nonadienamide 
N
H
O 61 
40 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) Toxicity data 
required. 
No longer supported 
by Industry (DG 
SANCO, 2012). 
16.094 
1596 
N-Ethyl (2E,6Z)-
nonadienamide N
H
O
 
61 
88 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d) Toxicity data 
required. 
No longer supported 
by Industry (DG 
SANCO, 2014). 
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(a): EU MSDI: Amount added to food as flavour in (kg / year) × 10E9 / (0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365) = µg/capita/day. 
(b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): Procedure steps, intake estimates, NOAEL, genotoxicity. 
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DOCUMENTATION PROVIDED TO EFSA 
1. Bauter MR, 2013. Piperine: a 90-day dietary study in rats. Product Safety Labs. Study no. 35233. 
May 23, 2013. Unpublished report submitted by EFFA to FLAVIS Secretariat. 
2. DG SANCO (Directorate General for Health and Consumer Affairs), 2012. Information from DG 
SANCO 07/02 2012, concerning two lists of 85 and 15 non-supported substances and one list of 
30 substances for which no data have been submitted or which are duplicates. FLAVIS.2.23rev1. 
3. EFFA (European Flavour and Fragrance Association), 2004. EFFA Poundage Survey 2004: 
European inquiry on volume use. Private communication to the Flavor and Extract Manufacturers 
Association (FEMA) and the International Organization of the Flavor Industry (IOFI). 
Unpublished data. 
4. EFFA (European Flavour Association), 2010. EFFA Letters to EFSA for clarification of 
specifications and isomerism for which data were requested in published FGEs. 
5. EFFA (European Flavour Association), 2013. Addendum of Additional Data Relevant to the 
Flavouring Group Evaluation of Chemical Group 33 (Annex I of 1565/2000/EC), aliphatic and 
aromatic amines and amides evaluated by JECFA (65th meeting), as evaluated by EFSA in 
FGE.86Rev1. Addendum to FGE.86Rev1. 05/29/2013. FLAVIS/8.212. 
6. EFFA (European Flavour Association), 2014. E-mail from EFFA to FLAVIS Secretariat, Danish 
Food Institute, Technical University of Denmark, dated 26 February 2014. Information on 
substance [FL-no: 16.013] in FGE.86Rev2. FLAVIS/8.229. 
7. Flavour Industry, 2004a. Unpublished information submitted by Flavour Industry to DG SANCO 
and forwarded to EFSA. A-86. 
8. Flavour Industry, 2004b. Unpublished information submitted by Flavour Industry to DG SANCO 
and forwarded to EFSA. A-86. 
9. Flavour Industry, 2013. Unpublished information submitted by Flavour Industry to FLAVIS 
Secretariat. A-86rev1 [FL-no: 16.091]. FLAVIS/8.225. 
10. Koetzner L, 2013a. Deca-(2E,4E)-dienoic acid isobutyl-amide: a 90-day dietary study in rats. 
Product Safety Labs. Study no. 35493. July 31, 2013. Unpublished report submitted by EFFA to 
FLAVIS Secretariat. 
11. Koetzner L, 2013b. Deca-(2E,4E)-dienoic acid isobutyl-amide: palatability/toxicity study: a 14-
day dietary study in rats. Product Safety Labs. Study no. 35337. April 19, 2013. Unpublished 
report submitted by EFFA to FLAVIS Secretariat. 
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APPENDIX A 
Table 6:  Normal and Maximum use levels (mg/kg) available for JECFA evaluated Substances 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
11.002 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.004 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.005 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.007 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
1 
5 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.015 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.016 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.018 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.020 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.021 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.023 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.025 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
11.026 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
14.080 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
14.133 0.4 0.1 0.4 0.4 - 1 0.2 2 0.2 0.2 - - 0.1 0.2 - 1 1 0.2 
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Table 6:  Normal and Maximum use levels (mg/kg) available for JECFA evaluated Substances 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
2 0.5 2 2 - 5 1 10 1 1 - - 0.5 1 - 5 5 1 
14.141 4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
2 
10 
0.2 
1 
0.2 
1 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
16.006 - 
- 
- 
- 
- 
- 
- 
- 
10 
300 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
16.052 0.4 
2 
0.1 
0.5 
0.4 
2 
0.4 
2 
- 
- 
1 
5 
0.2 
1 
1 
5 
0.1 
0.4 
0.1 
0.4 
- 
- 
- 
- 
0.1 
0.5 
0.2 
1 
- 
- 
1 
5 
1 
5 
0.2 
1 
16.091 0.02 
1 
0.02 
1 
0.2 
10 
- 
- 
- 
- 
2 
100 
- 
- 
0.2 
10 
0.02 
1 
0.02 
1 
- 
- 
- 
- 
0.02 
1 
- 
- 
2 
100 
2 
100 
0.02 
1 
0.02 
1 
16.092 0.4 
4 
0.4 
4 
0.4 
4 
- 
- 
- 
- 
40 
400 
- 
- 
4 
40 
0.4 
4 
0.4 
4 
- 
- 
- 
- 
0.4 
4 
- 
- 
40 
400 
40 
400 
0.4 
4 
0.4 
4 
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Table 7:  Estimated intakes based on the MSDI- and the mTAMDI approach 
FL-no EU Register name MSDI – EU 
(µg/capita/day) 
MSDI – USA 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
11.001 3-Methylbutylamine 24 0.07  Class I 1800 
11.002 Isobutylamine 0.012 0.09 340 Class I 1800 
11.003 Butylamine 89 0.01  Class I 1800 
11.004 Propylamine 0.012 0.02 340 Class I 1800 
11.005 sec-Butylamine 0.012 2 340 Class I 1800 
11.009 Trimethylamine 130 70  Class I 1800 
11.015 Ethylamine 0.012 0.2 340 Class I 1800 
11.016 Hexylamine 0.024 0.007 340 Class I 1800 
11.018 Isopropylamine 0.012 0.02 340 Class I 1800 
11.020 2-Methylbutylamine 0.012 0.02 340 Class I 1800 
11.021 Pentylamine 0.037 0.2 340 Class I 1800 
11.023 Triethylamine 0.073 0.9 340 Class I 1800 
11.025 Trimethylamine oxide 2.3 0.09 340 Class I 1800 
11.026 Tripropylamine 0.012 0.02 340 Class I 1800 
16.092 N,N-Dimethyl menthyl succinamide 61 88 15000 Class I 1800 
11.006 Phenethylamine 0.075 0.05  Class II 540 
11.007 2-(4-Hydroxyphenyl)ethylamine 0.012 0.02 340 Class II 540 
14.010 Piperidine 88 96  Class II 540 
14.064 Pyrrolidine 0.12 2  Class II 540 
14.080 2-Acetyl-1-pyrroline 0.012 0.1 340 Class II 540 
14.133 2-Methylpiperidine 0.012 0.002 340 Class II 540 
14.141 Piperazine 0.012 0.002 600 Class II 540 
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Table 7:  Estimated intakes based on the MSDI- and the mTAMDI approach 
FL-no EU Register name MSDI – EU 
(µg/capita/day) 
MSDI – USA 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
14.167 1-Pyrroline 0.012 0.4  Class II 540 
16.013 N-Ethyl-2-isopropyl-5-methylcyclohexane carboxamide 0.4 127  Class III 90 
16.053 2-Isopropyl- N,2,3-trimethylbutanamide 24 1054  Class III 90 
11.017 N-Isopentylidene isopentylamine 0.012 0.01  Class III 90 
14.003 Piperine 6.2 0.07  Class III 90 
16.006 N-Nonanoyl 4-hydroxy-3-methoxybenzylamide 6.0 0.07 1300 Class III 90 
16.052 1,6-Hexalactam 0.012 0.002 200 Class III 90 
16.091 Deca-(2E,4E)-dienoic acid isobutyl-amide 11 83 770 Class III 90 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practice 
ID  Identity 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
SCF  Scientific Committee on Food 
WHO  World Health Organisation 
